HROW Harrow Health Inc

P/E --
Forward P/E 277.78
Price/Sales 5.84
Beta 0.283
Div Yield --
Market Cap --

Company Analysis

Latest News

Harrow Faces Growth Scrutiny, as Grow Funds Exits After Earnings Miss

Harrow Faces Growth Scrutiny, as Grow Funds Exits After Earnings Miss

Grow Funds exited its position in Harrow, Inc. on June 25, 2026, following disappointing earnings. This development places the company's 2026 revenue guidance...

🟢 Harrow Health Inc is trading 5.2% up today after reaffirming 2026 revenue guidance

Harrow Health Inc is trading 5.2% up today at $40.40, extending a strong multi-day rebound from early June lows. • The move follows the company's recent...

🟢 Harrow Health Inc is trading 5.3% up today as VERKAZIA relaunch rally continues

Harrow Health Inc is trading at $39.65 (up 5.3%) as the U.S. relaunch of its VERKAZIA ophthalmic treatment continues to fuel a sharp multi-day advance. •...

🟢 Harrow Health Inc is trading 5.14% up today as VERKAZIA relaunch fuels extended rally

Harrow Health Inc is trading 5.14% up today at $39.59, extending a significant rally that began on June 10. • The primary catalyst for the move is the...

🟢 Harrow Health Inc is trading 5.0% up today as VERKAZIA relaunch fuels extended rally

Harrow Health Inc is trading 5.0% up now at $37.70, extending its sharp rally from June 10 after the re-launch of its prescriptive VKC eye treatment, VERKAZIA,...

🟢 Harrow Health Inc is trading 10.25% up today on VERKAZIA eye treatment re-launch

Harrow Health Inc is trading at $36.89 (+10.25%) after the re-launch of its prescriptive VKC eye treatment, VERKAZIA, sparked renewed investor optimism. • The...

🟢 Harrow Health Inc is trading 7% up today on VERKAZIA eye treatment re-launch

Harrow Health Inc is trading 7% up at $35.81 following the re-launch of its prescriptive VKC eye treatment, VERKAZIA, which has sparked renewed investor...

🟢 Harrow Health Inc is trading 6.6% higher after announcing the re-launch of its VKC treatment, VERKAZIA®

Harrow Health Inc is trading 6.6% higher at $35.65 after the company announced the re-launch of VERKAZIA®, a prescription therapy for the allergic eye disease...

🟢 Harrow Health Inc is trading 5.5% up as new investor presentation highlights growth outlook

Harrow Health Inc is trading at $35.15 (5.5% up) after the company provided a fresh business outlook to investors. • On June 3, the company released a new...